BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15710258)

  • 21. Thalidomide in cancer medicine.
    Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA
    Ann Oncol; 2004 Aug; 15(8):1151-60. PubMed ID: 15277253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
    Breitkreutz I; Anderson KC
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thalidomide treatment in multiple myeloma.
    Strasser K; Ludwig H
    Blood Rev; 2002 Dec; 16(4):207-15. PubMed ID: 12350364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.
    D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS
    Semin Oncol; 2001 Dec; 28(6):597-601. PubMed ID: 11740816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy].
    Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Mödder U
    Radiologe; 2002 Mar; 42(3):222-30. PubMed ID: 11963240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
    Mark TM; Coleman M; Niesvizky R
    Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory drugs in multiple myeloma.
    Zangari M; Elice F; Tricot G
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1411-8. PubMed ID: 16255679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of plasma cell dyscrasias with lenalidomide.
    Dimopoulos MA; Kastritis E; Rajkumar SV
    Leukemia; 2008 Jul; 22(7):1343-53. PubMed ID: 18509355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Lenalidomide in hematological malignancies---review].
    Jin X; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide - current understanding of mechanistic properties.
    Tageja N
    Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thalidomide in oncological and hematological diseases].
    Kivivuori SM; Anttila P
    Duodecim; 2010; 126(12):1413-9. PubMed ID: 20617746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
    Kumar A; Porwal M; Verma A; Mishra AK
    J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
    Zeidner JF; Foster MC
    Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.